Conditions: Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma
Keywords: Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma Erwinaze asparaginase Eusa Pharma Pharmacokinetic study NSAA
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 30
Healthy volunteers: no

Brief summary:
This study will utilize Erwinaze via intravenous administration in patients between the ages of 1 and 30 who have experienced an allergy to their frontline therapy. The study will determine the proportion of patients with 2 day nadir serum asparaginase activity levels that are \>0.1 IU/mL during the first 2 weeks of treatment with 3 times per week IV dosing.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: asparaginase Erwinia chrysanthemi
Intervention descriptions: intervention 1: None

Protocol document: